Oric Pharmaceuticals Stock Quote ORIC - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

11.77

Bid

11.61

Ask

12.13

Volume

658,678

11.3997 Day's Range 12.085

5.27 52 Week Range 16.65

Market Cap

793.561M

Previous Close

11.24

Open

11.46

Last Trade

12.12

Last Trade Time

Financial Volume

$ 7,863,128

VWAP

11.9377

Average Volume (3m)

488,884

Shares Outstanding

67,422,307

Dividend Yield

PE Ratio

-7.96

Earnings Per Share (EPS)

-1.49

Revenue

Net Profit

-100.7M

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company h... ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101, ORIC-944, ORIC-114, and ORIC-533. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.oricpharma.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

Oric Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ORIC. The last closing price for Oric Pharmaceuticals was $11.24. Over the last year, Oric Pharmaceuticals shares have traded in a share price range of $ 5.27 to $ 16.65.

Oric Pharmaceuticals currently has 67,422,307 shares outstanding. The market capitalization of Oric Pharmaceuticals is $757.83 million. Oric Pharmaceuticals has a price to earnings ratio (PE ratio) of -7.96.

ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.53	14.94140625	10.24	12.085	10.03	368430	10.8761354	CS
4	4.7	66.4780763791	7.07	12.085	6.94	639856	9.64408791	CS
12	2	20.4708290686	9.77	12.085	6.33	488884	8.89644549	CS
26	1.3	12.4164278892	10.47	16.65	6.33	533280	10.83125943	CS
52	3.14	36.3847045191	8.63	16.65	5.27	465830	9.47038498	CS
156	-5.53	-31.9653179191	17.3	26.7	2.36	412113	7.92337035	CS
260	-14.23	-54.7307692308	26	40.81	2.36	360008	11.80150505	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	259.77k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.45M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M